Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roxana S Dronca

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Immunomodulatory antibody therapy of cancer: the closer, the betterRoxana S Dronca, Haidong Dong
Frontiers in Oncology|February 21, 2015
A gender factor in shaping T-cell immunity to melanomaRoxana S Dronca, Haidong Dong
Nature Clinical Practice. Oncology|July 24, 2008
VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemiaRoxana S Dronca, David P Steensma
Mayo Clinic Proceedings|April 2, 2014
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanomaDarshil J Shah, Roxana S Dronca
SOJ Immunology|April 10, 2018
A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapyHaidong Dong, Yiyi Yan, Roxana S Dronca, et al.
Mayo Clinic Proceedings|July 6, 2019
Immune Checkpoint Inhibitor ToxicitiesJulian A Marin-Acevedo, Razvan M Chirila, Roxana S Dronca
Immunotherapy|October 28, 2016
BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanomaRoxana S Dronca, Aaron S Mansfield, Sean S Park, et al.
Genes & Diseases|February 12, 2020
Paradox-driven adventures in the development of cancer immunology and immunotherapyWhitney Barham, Joanina K Gicobi, Yiyi Yan, et al.
Mayo Clinic Proceedings|August 6, 2014
Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--IJustin C Moser, Roxana S Dronca, Svetomir N Markovic, et al.
Future Oncology (London, England)|November 15, 2012
Personalized therapy for metastatic melanoma: could timing be everything?Roxana S Dronca, Alexey A Leontovich, Wendy K Nevala, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Immunomodulatory antibody therapy of cancer: the closer, the betterRoxana S Dronca, Haidong Dong
Frontiers in Oncology|February 21, 2015
A gender factor in shaping T-cell immunity to melanomaRoxana S Dronca, Haidong Dong
Nature Clinical Practice. Oncology|July 24, 2008
VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemiaRoxana S Dronca, David P Steensma
Mayo Clinic Proceedings|April 2, 2014
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanomaDarshil J Shah, Roxana S Dronca
SOJ Immunology|April 10, 2018
A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapyHaidong Dong, Yiyi Yan, Roxana S Dronca, et al.
Mayo Clinic Proceedings|July 6, 2019
Immune Checkpoint Inhibitor ToxicitiesJulian A Marin-Acevedo, Razvan M Chirila, Roxana S Dronca
Immunotherapy|October 28, 2016
BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanomaRoxana S Dronca, Aaron S Mansfield, Sean S Park, et al.
Genes & Diseases|February 12, 2020
Paradox-driven adventures in the development of cancer immunology and immunotherapyWhitney Barham, Joanina K Gicobi, Yiyi Yan, et al.
Mayo Clinic Proceedings|August 6, 2014
Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--IJustin C Moser, Roxana S Dronca, Svetomir N Markovic, et al.
Future Oncology (London, England)|November 15, 2012
Personalized therapy for metastatic melanoma: could timing be everything?Roxana S Dronca, Alexey A Leontovich, Wendy K Nevala, et al.
Pageof 6